| ABIO - ARCA biopharma Inc (Healthcare: Biotechnology) | Projected Earnings Date: 0000-02-29 (Delayed quote data 2024-08-30) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| ARCA biopharma Inc is a clinical development stage biopharmaceutical company. It applies precision medicine approach to develop genetically targeted therapies for cardiovascular diseases. The company's lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, viruses, initially focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation, in patients with chronic heart failure. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |